IN2013MU01127A - - Google Patents

Info

Publication number
IN2013MU01127A
IN2013MU01127A IN1127MU2013A IN2013MU01127A IN 2013MU01127 A IN2013MU01127 A IN 2013MU01127A IN 1127MU2013 A IN1127MU2013 A IN 1127MU2013A IN 2013MU01127 A IN2013MU01127 A IN 2013MU01127A
Authority
IN
India
Prior art keywords
tigecycline
solution
reconstitution
maltose
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Parikh Dhara
Patel Aditya
Bhaskar Dr Pallerla
Sehgal Ashish
Original Assignee
Astron Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54258937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU01127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astron Res Ltd filed Critical Astron Res Ltd
Priority to IN1127MU2013 priority Critical patent/IN2013MU01127A/en
Priority to ES14782395T priority patent/ES2766832T3/es
Priority to SI201431458T priority patent/SI2978426T1/sl
Priority to EP14782395.9A priority patent/EP2978426B1/en
Priority to HUE14782395A priority patent/HUE047307T2/hu
Priority to CA2905645A priority patent/CA2905645C/en
Priority to PT147823959T priority patent/PT2978426T/pt
Priority to PL14782395T priority patent/PL2978426T3/pl
Priority to US14/779,889 priority patent/US9511145B2/en
Publication of IN2013MU01127A publication Critical patent/IN2013MU01127A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN1127MU2013 2013-03-26 2013-03-26 IN2013MU01127A (he)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1127MU2013 IN2013MU01127A (he) 2013-03-26 2013-03-26
ES14782395T ES2766832T3 (es) 2013-03-26 2014-03-25 Composición estable de tigeciclina
SI201431458T SI2978426T1 (sl) 2013-03-26 2014-03-25 Stabilni sestavek tigeciklina
EP14782395.9A EP2978426B1 (en) 2013-03-26 2014-03-25 Stable tigecycline composition
HUE14782395A HUE047307T2 (hu) 2013-03-26 2014-03-25 Stabil tigeciklin-készítmény
CA2905645A CA2905645C (en) 2013-03-26 2014-03-25 Stable tigecycline composition
PT147823959T PT2978426T (pt) 2013-03-26 2014-03-25 Composição de tigeciclina estável
PL14782395T PL2978426T3 (pl) 2013-03-26 2014-03-25 Stabilna kompozycja tygecykliny
US14/779,889 US9511145B2 (en) 2013-03-26 2014-03-25 Stable tigecycline composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1127MU2013 IN2013MU01127A (he) 2013-03-26 2013-03-26

Publications (1)

Publication Number Publication Date
IN2013MU01127A true IN2013MU01127A (he) 2015-05-01

Family

ID=54258937

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1127MU2013 IN2013MU01127A (he) 2013-03-26 2013-03-26

Country Status (9)

Country Link
US (1) US9511145B2 (he)
EP (1) EP2978426B1 (he)
CA (1) CA2905645C (he)
ES (1) ES2766832T3 (he)
HU (1) HUE047307T2 (he)
IN (1) IN2013MU01127A (he)
PL (1) PL2978426T3 (he)
PT (1) PT2978426T (he)
SI (1) SI2978426T1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063468A1 (en) * 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870059A (en) * 1985-11-27 1989-09-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Dehydration of hydrous matter with anhydrous maltose
DE68908175T2 (de) 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
DE19936281C2 (de) 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
PL1858488T5 (pl) 2005-03-14 2024-01-03 Wyeth Llc Kompozycje tygecykliny i sposoby wytwarzania
AR055336A1 (es) 2005-06-16 2007-08-22 Wyeth Corp Proeso de elaboracion para la produccion de tigeciclina como un polvo reconstituible, polvo de tigeciclina liofilizado y producto hecho mediante el proceso
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
WO2010017273A2 (en) 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
BRPI0916885B8 (pt) 2008-08-28 2021-05-25 Astrazeneca Ab composição farmacêutica
CN102970992B (zh) * 2010-05-12 2016-07-06 莱姆派克斯制药公司 四环素组合物

Also Published As

Publication number Publication date
SI2978426T1 (sl) 2020-03-31
US9511145B2 (en) 2016-12-06
EP2978426B1 (en) 2019-11-13
EP2978426A2 (en) 2016-02-03
PT2978426T (pt) 2020-02-14
CA2905645C (en) 2021-02-16
CA2905645A1 (en) 2014-10-16
EP2978426A4 (en) 2016-11-30
US20160058865A1 (en) 2016-03-03
HUE047307T2 (hu) 2020-04-28
PL2978426T3 (pl) 2020-05-18
ES2766832T3 (es) 2020-06-15

Similar Documents

Publication Publication Date Title
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12015502797B1 (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
MX2020005181A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
IL240731B (he) נוגדן הקושר את תת–יחידה p19 של il–23 תהליך ייצורו, תכשיר רוקחי המכיל אותו ושימושו בטיפול בסרטן
IN2013CN09704A (he)
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
CA2905610C (en) Hyaluronic acid derivatives
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12015500794A1 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
UY36250A (es) Forma cristalina de sofosbuvir y proceso para su preparación
IN2013MU03641A (he)
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX360048B (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
MX2015016603A (es) Composiciones de corticosteroides.
GB2527233A (en) Composition comprising hydrocortisone
IN2013MU01127A (he)
IN2013CH05282A (he)
IN2013CH04314A (he)
WO2014167575A3 (en) Stable tigecycline composition